[{"id":"73e3eec7-4518-48c4-b46f-3dd2b5e30704","acronym":"","url":"https://clinicaltrials.gov/study/NCT03835819","created_at":"2021-01-18T18:56:17.574Z","updated_at":"2025-02-25T16:08:53.728Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)","source_id_and_acronym":"NCT03835819","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" FOLR1 • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSH6 expression","tags":["FOLR1 • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 06/04/2024","primary_completion_date":" 06/04/2024","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-11-08"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"57e5c5b5-7228-43b4-85dd-3170c48f767f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03396926","created_at":"2021-01-18T16:45:49.183Z","updated_at":"2025-02-25T16:07:25.765Z","phase":"Phase 2","brief_title":"Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03396926","lead_sponsor":"University of California, San Francisco","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSH6 expression","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 04/18/2018","start_date":" 04/18/2018","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2024-03-07"},{"id":"eb7e9f6f-0f79-4bb6-a9ca-432b503df985","acronym":"GARNET","url":"https://clinicaltrials.gov/study/NCT02715284","created_at":"2021-01-17T17:14:10.274Z","updated_at":"2024-07-02T16:35:39.382Z","phase":"Phase 1","brief_title":"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02715284 - GARNET","lead_sponsor":"Tesaro, Inc.","biomarkers":" EGFR • ALK • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK translocation • MSH6 expression","tags":["EGFR • ALK • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK translocation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 740","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 10/27/2027","study_completion_date":" 10/27/2027","last_update_posted":"2023-08-22"},{"id":"e719e53a-348e-4f61-a2ec-8427efdc6994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846867","created_at":"2023-05-06T14:04:17.161Z","updated_at":"2024-07-02T16:35:48.741Z","phase":"Phase 1/2","brief_title":"Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients","source_id_and_acronym":"NCT05846867","lead_sponsor":"Akeso","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • MSH6 expression","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2023-05-08"},{"id":"0a5b61b3-7667-454c-b61f-affb10bb9e77","acronym":"3CI Study","url":"https://clinicaltrials.gov/study/NCT04500548","created_at":"2021-01-18T21:33:32.102Z","updated_at":"2024-07-02T16:36:04.140Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","source_id_and_acronym":"NCT04500548 - 3CI Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression","tags":["TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 06/21/2022","study_completion_date":" 06/21/2022","last_update_posted":"2022-09-12"},{"id":"f1d4236e-f4b2-4600-82e7-b8536383bf33","acronym":"SAMCO","url":"https://clinicaltrials.gov/study/NCT03186326","created_at":"2021-01-18T15:42:42.125Z","updated_at":"2024-07-02T16:36:05.186Z","phase":"Phase 2","brief_title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","source_id_and_acronym":"NCT03186326 - SAMCO","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS mutation • MSH6 expression","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • Bavencio (avelumab) • oxaliplatin • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-08-19"}]